Isoniazid completion rates for latent tuberculosis infection among college students managed by a community pharmacist

Journal of American College Health

Volumn 57, Issue 5, 2009, Pages 553-556

  Hess, Karl ^a   Goad, Jeffery ^b   Wu, Joanne ^b   Johnson, Kathleen ^b  

^a UNIVERSITY OF HEALTH SCIENCES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Community pharmacy; Isoniazid; Latent tuberculosis infection; Medication adherence

Indexed keywords

ISONIAZID; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; FEMALE; HUMAN; MALE; ORGANIZATION AND MANAGEMENT; PATIENT COMPLIANCE; PHARMACY; RETROSPECTIVE STUDY; STATISTICS; STUDENT; TIME; TUBERCULOSIS; UNIVERSITY;

ANTITUBERCULAR AGENTS; COMMUNITY PHARMACY SERVICES; FEMALE; HUMANS; ISONIAZID; MALE; MEDICATION ADHERENCE; RETROSPECTIVE STUDIES; STUDENTS; TIME FACTORS; TUBERCULOSIS; UNIVERSITIES; YOUNG ADULT;

EID: 65349177180     PISSN: 07448481     EISSN: None     Source Type: Journal    
DOI: 10.3200/JACH.57.5.553-556     Document Type: Article

References (17)

1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA. 1999;282:677-686.
2. World Health Organization. Global tuberculosis control: surveillance, planning, financing. http://www.who.int/tb/publications/ global-report/en. Accessed June 19, 2006.
3. Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 2005. http://www.cdc.gov/tb/surv/ surv2005/default.htm. Accessed June 19, 2006.
4. McKenna MT, McCray E, Onorato I. The epidemiology of tuberculosis among foreign-born persons in the United States, 1986-1993. N Eng J Med. 1995;332:1071-1076.
5. Talbot EA, Moore M, McCray E, Binkin NJ. Tuberculosis among foreign-born persons in the United States, 1993-1998. JAMA. 2000;284:2894-2900.
6. Centers for Disease Control and Prevention. Controlling tuberculosis in the United States. MMWR Morb Mortal Wkly Rep. 2005;54:1-69.
7. Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2000;49:1-43.
8. Dooley KE, Sterling TR. Treatment of latent tuberculosis infection: challenges and prospects. Clin Chest Med. 2005;26:313-326.
9. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA. 1999;281:1014-1018.
10. LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med. 2003;168:443-447.
11. Coleman LT, Adams WC, Gong WC. Pharmacist as a primary-care provider in a tuberculosis clinic. Am J Health Syst Pharm. 1983;40:278-281.
12. Dayton CS. Pharmacist involvement in a tuberculosis outpatient clinic. Am J Health Syst Pharm. 1978;35:708-710.
13. Sterling TR, Bethel J, Goldberg SV, Weinfurter P, Yun L, Horsburgh CR. The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med. 2006;173:927-931.
14. Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for four months versus isoniazid for nine months. Am J Respir Crit Care Med. 2004;170:445-449.
15. Cook PP, Maldonado RA, Yarnell CT, Holbert D. Safety and completion rate of short-course therapy for treatment of latent tuberculosis infection. Clin Infect Dis. 2006;43:271-275
16. Tavitian SM, Spalek VH, Bailey RP. A pharmacist-managed clinic for treatment of latent tuberculosis infection in health care workers. Am J Health Syst Pharm. 2003;60:1856-1861.
17. Bollag B. Enrollment of foreign students holds steady. Chronicle of Higher Education. 2006;53(13):A44-46.